Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 13/20 | 0.80 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30456093 | 1.00 | RIPK1 (0.80) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL22608921 | 1.00 | RIPK1 (0.80) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL22608900 | 1.00 | RIPK1 (0.80) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL28465510 | 0.92 | RIPK1 (0.77) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL28465505 | 0.92 | RIPK1 (0.77) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL25816897 | 0.92 | RIPK1 (0.68) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL30798992 | 0.89 | RIPK1 (1.00) | RIPK1CHRM4CHRM2CHRM5CHRM1 | |
| SCHEMBL25275978 | 0.89 | RIPK1 (0.72) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL25238695 | 0.89 | RIPK1 (0.72) | RIPK1KMOCHRM4CHRM2CHRM5 | |
| SCHEMBL25279343 | 0.89 | RIPK1 (0.72) | RIPK1KMOCHRM4CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | claimed |
| EP-3732176-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-11-04 | — | — | EP | claimed |
| CN-111741957-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-10-02 | — | — | CN | claimed |
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| CN-111741957-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192676-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 416/4885KMO 1458/4885CHRM4 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.